♥ HF Guideline NavigatorESC 2026

6 › 6.2 › 6.2.2

6.2.2 Cardiac resynchronization therapy

Pages 40–41 · open in PDF

Recommendations in this section

  • Class ILevel ACRT is recommended in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, in SR with LBBB and QRS duration ≥ 150 ms in order to improve symptoms and reduce the risk of hospitalizations and death.
  • Class IIaLevel B1An upgrade to CRT should be considered in patients with an LVEF ≤ 35% who have received a conventional pacemaker or an ICD and subsequently develop worsening HF despite optimal FMT and who have a significant proportion of RV pacing in order to reduce the risk of HFH or death.
  • Class IIaLevel B1CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and death.
  • Class IIaLevel CCRT should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration ≥ 150 ms in order to improve symptoms and reduce morbidity and death.
  • Class IIaLevel CCRT should be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death.
  • Class IIbLevel CCRT may be considered in patients with symptomatic HFrEF, LVEF ≤ 35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce morbidity and death.
  • Class IIbLevel CInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be conducted prior to CRT implantation.
  • Class IIILevel ACRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-degree AV block.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 40 · PDF

40 6.2.2. Cardiac resynchronization therapy

6.2.2.1. Cardiac resynchronization therapy for heart failure caused by abnormal cardiac conduction Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to conduction abnormalities (Figure 9 and Section 5.3.3). In patients with HF, where no other cause of HF other than abnormal cardiac conduction can be found, and there is a low likelihood of LVEF improvement, planning for CRT implantation may be considered early—even before full FMT uptitration.

6.2.2.2. Right ventricular pacing-induced heart failure As expected from the effects of ectopic cardiac stimulation, RV pacing leads to HFrEF in some patients.202,413 The incidence of pacemaker- or RV pacing-induced HF varies between 5.9% and 39%, depending on the definition.202,236–239 In the recent BUDAPEST-CRT Upgrade trial, upgrading to CRT-D significantly reduced death and HFH in patients with ≥20% RV pacing burden and QRS ≥150 ms (HR 0.27; P<.001). The BUDAPEST-CRT Upgrade trial is the first RCT and included only 360 patients in total. Therefore, CRT-D upgrade should be considered in such patients.202,237,238,412,414

6.2.2.3. Timing of cardiac resynchronization therapy implantation The timing of CRT in relation to hospitalizations has not been addressed by RCTs. In an observational study of 64 968

Figure 10 Indications for cardiac resynchronization therapy in heart failure. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HFrEF, heart failure with reduced ejection fraction; ICD, Implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction. In the decision on device implantation consider the following: patient preference, likely benefit of ICD/CRT at the patient’s age, frailty and comorbidities, risk of complications, venous access issues. aUptitration to the highest tolerated doses of HFrEF FMT (see Table 11). bInitiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and mortality, although reassessment of LVEF should be conducted prior to CRT implantation. (Class IIb).

In carefully selected patients with HFrEF, CRT improves cardiac function, QoL, and reduces hospitalizations and death. Landmark RCTs support CRT use across a range of HF severity.388–398 The first RCT to address the effects of CRT on morbidity and mortality was COMPANION388 in which CRT with pacemaker (CRT-P) and CRT with defibrillator (CRT-D) reduced the composite endpoint of all-cause death and hospitalizations for any cause by 20%. A reduction in all-cause death was shown with CRT-D, but not with CRT-P. In contrast, in the CARE-HF trial,392 which randomized participants to medical therapy with or without CRT-P, CRT-P reduced all-cause death and HFH. In the MADIT-CRT trial, in which 1820 patients in NYHA classes I and II were randomized to CRT-D or ICD, CRT-D reduced allcause death or HF events by 34%.397 In the REVERSE trial,396 which also involved patients in NYHA classes I and II with primary prevention ICD indications, CRT improved LVEF and reduced HFH. Importantly, in the 5-year follow-up of REVERSE, annualized death was low at 2.9% in patients randomized to ‘CRT-on’.399 Together, these findings have provided compelling evidence for using CRT across the spectrum of severity of HFrEF. For landmark trials of CRT, see Supplementary data online, Table S10.388,389,392,396–398,400–412 Figure 10 provides an overview of factors to consider when evaluating patients for CRT.

Page 41 · PDF

Recommendation Table 7 — Recommendations for cardiac resynchronization therapy implantation (see Evidence Tables 49–58) Recommendations

CRT is recommended in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, in SR with LBBB and QRS duration ≥150 ms in order to improve symptoms and reduce the risk of hospitalizations and death.388– An upgrade to CRT should be considered in patients with an LVEF ≤35% who have received

optimal FMT and who have a significant proportion of RV pacing in order to reduce the risk of HFH or death.412

indication for ventricular pacing for high-degree AV block in order to reduce the risk of HFH and

death.409 CRT should be considered in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration ≥150 ms in order to improve symptoms and reduce morbidity and death.388–398 CRT should be considered in patients with symptomatic HFrEF, LVEF ≤35%, despite optimal FMT, who are in SR with LBBB QRS morphology and QRS duration of 130–149 ms in order to improve symptoms and reduce

optimal FMT, who are in SR with non-LBBB QRS morphology and QRS duration of 130–149 ms

in order to improve symptoms and reduce morbidity and death.391,397 Initiation of FMT and planning for CRT implantation may be considered simultaneously in patients with symptomatic HFrEF, an LBBB with QRS ≥150 ms, and LVEF ≤35%, to improve symptoms and reduce morbidity and death, although reassessment of LVEF should be CRT is not recommended in patients with a QRS duration <130 ms who do not have an indication for pacing due to high-degree AV block.410,424,425

AV, atrioventricular; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverterdefibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricular; SR, sinus rhythm. a Class of recommendation. b Level of evidence.

Conduction system pacing (CSP), including His bundle and left bundle branch area pacing, aims to engage the Purkinje network for rapid and synchronous LV activation.426 Left bundle branch area pacing may prove to be a feasible alternative to CRT when implantation is challenging. However, no RCT with patientcentred outcomes has evaluated the efficacy or long-term safety of CSP in HFrEF. Therefore, no recommendations can currently be made. See Evidence Table 22 and Supplementary data online, Section S3.1.3 for further details.427–433

morbidity and death.390,417 Continued

In the same way that FMT implies lifelong adherence to drugs, a CIED requires a lifelong commitment to device follow-up. For the clinician, skills in interpretation of device-derived electrograms, device-related problem solving, and programming are essential.434,435 For ICDs, routine defibrillation testing of shock efficacy does not reduce arrhythmic death and is therefore no longer recommended.436 Programming a high-rate cut-off and long detection intervals between detection of ventricular tachycardia and antitachycardia pacing or shocks dramatically reduce inappropriate shocks and unnecessary ICD therapy.436,437 At follow-up, the RV pacing burden as well as the intrinsic QRS duration are an important focus for deciding whether to upgrade from an ICD to a CRT-D device. In patients with a CRT device, regular follow-up and optimization should be implemented, as CRT programming and FMT may require further optimization after implantation.435 Appropriate programming of atrioventricular intervals and optimal LV lead vectors are required to optimize CRT response. In patients

conducted prior to CRT implantation.418–423

6.2.4. Cardiac implantable electronic device programming and follow-up

CRT, rather than RV pacing, should be considered in patients with HFrEF regardless of NYHA class or QRS width who have an

symptomatic HFrEF, LVEF ≤35%, despite

6.2.3. Conduction system pacing

a conventional pacemaker or an ICD and subsequently develop worsening HF despite

CRT may be considered in patients with

patients undergoing CRT, the combined endpoint of allcause death and HFH was lowest in patients with no HFH prior to implantation (9.7 per 100 person-years) and those who had CRT during the first HFH (11.1 per 100 personyears) compared with patients who had a CRT implantation within a year of their first HFH (17.3 per 100 patientyears).415 In a study of 15 619 CRT-eligible patients with HF in the Get With The Guidelines-HF registry, all-cause death was lower in those who received CRT implantation during HFH (adjusted HR 0.63; P<.0001) compared with patients who did not have CRT.416 A lower rate HF rehospitalization was observed in patients with CRT implanted during the first hospitalization (adjusted HR 0.64; P<.0001), but not in those prescribed CRT at discharge. As HFH is a critical step in the progression of HF, it may be beneficial to implant CRT at an early stage in patients who are most likely to benefit (LVEF ≤35%, LBBB with QRS ≥150 ms), ideally before an HFH has occurred.